Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

Strahlentherapie und Onkologie

Volumn 188, Issue 9, 2012, Pages 823-832

  Saki, M ^a   Toulany, M ^a   Sihver, W ^b   Zenker, M ^b   Heldt, J M ^b   Mosch, B ^b   Pietzsch, H J ^b   Baumann, M ^c   Steinbach, J ^b   Rodemann, H P ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c Helmholtz Zentrum Dresden Rossendorf   (Germany)

Author keywords

90Y cetuximab; 90Yittrium; Cetuximab; EGFR; Head and neck squamous cell carcinoma

Indexed keywords

CETUXIMAB; CYCLOHEXYLDIETHYLENETRIAMINEPENTAACETIC ACID; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RADIOPHARMACEUTICAL AGENT; TYROSINE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL FRACTIONATION; CELL FUNCTION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GROWTH INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; INTERNALIZATION; IRRADIATION; ISOTOPE LABELING; KINETICS; NONHUMAN; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SKIN FIBROBLAST; TUMOR CELL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY, ADJUVANT; CRICETINAE; HUMANS; NEOPLASMS, EXPERIMENTAL; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL; YTTRIUM RADIOISOTOPES;

EID: 84866726279     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0121-4     Document Type: Article

References (47)

1. Johnson KA, Brown PH (2010) Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol 37:345-358
2. Riesterer O, Mason KA, Raju U et al (2009) Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. Radiother Oncol 92:383-387
3. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593-1611
4. Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 83:3825-3829
5. Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595-27602
6. Gerber DE, Choy H (2010) Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev 29:171-180
7. Krause M, Gurtner K, Deuse Y, Baumann M (2009) Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int J Radiat Biol 85:943-954
8. Gurtner K, Deuse Y, Butof R et al (2011) Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 99:323-330
9. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
10. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
11. Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191-2197
12. Zhang N, Erjala K, Kulmala J et al (2009) Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 92:388-392
13. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174
14. Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157-161
15. Dittmann K, Mayer C, Rodemann HP (2010) Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol 186:1-6
16. Dittmann K, Mayer C, Fehrenbacher B et al (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182-1189
17. Toulany M, Kasten-Pisula U, Brammer I et al (2006) Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12:4119-4126
18. Kriegs M, Kasten-Pisula U, Rieckmann T et al (2010) The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 9:889-897
19. Toulany M, Minjgee M, Kehlbach R et al (2010) ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. Radiother Oncol 97:338-345
20. Nieder C (2012) RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer. Strahlenther Onkol 188:194-195
21. Alongi F, Bignardi M, Garassino I et al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 188:49-55
22. Selzer E, Liederer S, Lemaire C et al (2011) Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 187:373-377
23. Niyazi M, Siefert A, Schwarz SB et al (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98:1-14
24. Liu Z, Liu Y, Jia B et al (2010) Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 9:2297-2308
25. Gemmete JJ, Mukherji SK (2011) Panitumumab (Vectibix). AJNR Am J Neuroradiol
26. Rades D, Wolff C, Nadrowitz R et al (2009) Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys 75:1226-1231
27. Rades D, Nadrowitz R, Buchmann I et al (2010) Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther Onkol 186:458-462
28. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493-507
29. Toulany M, Dittmann K, Baumann M, Rodemann HP (2005) Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol 74:117-129
30. Debucquoy A, Machiels JP, McBride WH, Haustermans K (2010) Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. Clin Cancer Res 16:2709-2714
31. Rodemann HP, Dittmann K, Toulany M (2007) Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83:781-791
32. Meyn RE, Munshi A, Haymach JV et al (2009) Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 92:316-322
33. Wang M, Morsbach F, Sander D et al (2011) EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 71:6261-6269
34. Bonner JA, Yang ES, Trummell HQ et al (2011) Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol 99:339-343
35. Milenic DE, Wong KJ, Baidoo KE et al (2008) Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23:619-631
36. Aerts HJ, Dubois L, Perk L et al (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123-131
37. Liao HJ, Carpenter G (2009) Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res 69:6179-6183
38. Jaramillo ML, Leon Z, Grothe S et al (2006) Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 312:2778-2790
39. Eiblmaier M, Meyer LA, Watson MA et al (2008) Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 49:1472-1479
40. Nordberg E, Friedman M, Gostring L et al (2007) Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 34:609-618
41. Gostring L, Chew MT, Orlova A et al (2010) Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol 36:757-763
42. Koi L, Bruechner K, Helbig L et al (2011) Combination of external and internal irradiation using radionuclide-labelled Cetuximab in FaDu human squamous cell carcinomas xenografted in nude mice. Wolsberg meeting series 9:60
43. Eke I, Cordes N (2011) Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother Oncol 99:279-286
44. Berger C, Krengel U, Stang E et al (2011) Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J Immunother 34:550-555
45. Yoshida T, Okamoto I, Okabe T et al (2008) Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 122:1530-1538
46. Li S, Schmitz KR, Jeffrey PD et al (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311
47. Patel D, Bassi R, Hooper A et al (2009) Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 34:25-32